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BACKGROUND: Previous studies have shown that age at menopause is an important indicator of duration of
endogenous estrogen exposure. The present study investigates whether combining more information on reproduc-
tive factors is useful in estimating individual total duration of exposure to endogenous estrogens. METHODS:
Bone mineral density (BMD) was used as operational outcome. The study population consisted of 3476 white
women living in Eindhoven, The Netherlands, aged 46–57 years, either pre- (n 5 2420) or postmenopausal
(n 5 1056). BMD of the lumbar spine was measured by dual X-ray absorptiometry. Information on reproductive
factors was obtained with questionnaires. RESULTS: The number of reproductive years explained 4.8% of the
variance in BMD, while age at menopause alone accounted for 3.6%. Duration of lactation or oral contraceptive
use did not add to the proportion of variance explained. The effect of reproductive years on BMD was stronger in
older women. No significant associations with BMD were found for other reproductive variables. The number of
miscarriages in premenopausal women (b 5 0.00760, SE 5 0.00357, P 5 0.03) explained only 0.16% of the var-
iance in BMD. CONCLUSIONS: We conclude that it is not necessary to use more reproductive factors besides age
at menopause and menarche in determining total duration of endogenous estrogen exposure.
Key words: bone mineral density/estrogen/premenopausal/postmenopausal/reproductive factors
Introduction
Most of the epidemiologic research on the association
between endogenous estrogens and cardiovascular disease
(van der Schouw et al., 1996; Jacobsen et al., 1997), breast
cancer (Verheul et al., 2000; Zheng et al., 2001), osteopo-
rosis (Cumming and Klineberg 1993, 1998; Eisman, 1998;
Jacobsen et al., 1998) and colorectal cancer (Kampman et al.,
1997; Slattery et al., 2001) has focused on individual repro-
ductive factors. Age at menopause and age at menarche seem
to be of overriding importance in determining total endogen-
ous estrogen exposure, but factors like pregnancy, regularity
and duration of the menstrual cycle, lactation and use of oral
contraceptives also play a role.
As a measure of endogenous estrogen exposure, sex hormone
levels in blood are not easily interpretable, because there is
huge variation in hormone levels through the menstrual cycle
and it is not clear which menstrual phase most adequately
reflects premenopausal hormone exposure (Sowers et al., 2003).
Bone mineral density (BMD) is considered a good
outcome parameter, since it is generally accepted that
endogenous estrogens and BMD are strongly associated
(Zhang et al., 2001).
Consistent associations have been reported between BMD
and either age at menarche (Kritz Silverstein and Barrett
Connor 1993; Ito et al., 1995), or age at menopause (Kritz
Silverstein and Barrett Connor 1993; Ito et al., 1995;
Parazzini et al., 1996), or the number of reproductive years
(Vico et al., 1992; Kritz Silverstein and Barrett Connor 1993;
Ito et al., 1995; Nguyen et al., 1995; Grainge et al., 2001).
The combination of age at menopause and age at menarche
in one measure appears to explain more of the variance in
bone mineral density than either variable individually (Kritz
Silverstein and Barrett Connor 1993). However, other repro-
ductive factors are also associated with BMD and may there-
fore be useful in refining the assessment of endogenous
estrogen exposure.
During pregnancy maternal estrogen levels markedly
increase (Speroff et al., 1989), which may have a beneficial
effect on BMD. However, during pregnancy and lactation the
demand of calcium is increased and some loss of bone
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calcium is to be expected (Khastgir et al., 1994). Several
epidemiologic studies show a significantly increased bone
density with increasing parity (Nguyen et al., 1995;
Tuppurainen et al., 1995) while others do not (Hamed et al.,
1992b; Johansson et al., 1993; Parazzini et al., 1996). During
lactation, estrogen production is suppressed (Rolland, 1995).
This relative shortage of estrogen during one or more breast-
feeding periods could theoretically lead to a lower bone den-
sity after the breastfeeding period. During breastfeeding loss
of bone mineral has been noted in several sites in the periph-
eral skeleton. Some studies have shown that the loss in bone
mineral is almost completely restored 6 to 12 months after
weaning and with the return of normal menses (Eisman,
1998). In other studies a negative effect (Lissner et al., 1991)
or no effect (Tuppurainen et al., 1995; Parazzini et al., 1996;
Grainge et al., 2001) of lactation on BMD has been found. It
is, however, not possible to distinguish between the potential
effect of a low estrogen exposure and the effect of an
increased demand for calcium.
Studies on the relationship between oral contraceptives
and bone density have shown conflicting results (Lindsay
et al., 1986; Recker et al., 1992; Murphy et al., 1993;
DeCherney, 1996; Vessey et al., 1998; Grainge et al., 2001).
As oral contraceptives, like hormone replacement therapy,
are a source of exogenous estrogens, one would expect them
to have a positive effect on bone density, although the dose
and type of estrogens are different from those used in hor-
mone replacement therapy.
The objective of this study is to investigate whether com-
bining information on these reproductive factors is useful in
estimating individual total duration of exposure to endoge-
nous estrogen. For this purpose, we investigate to what extent
the variation in BMD pre- and post-menopause can be
explained by differences in total endogenous estrogen
exposure and whether a more refined measure of endogenous
estrogen exposure adds to the predictive value for BMD of
the single factor ‘age at menopause’.
Subjects and methods
Study population
The screening of women for the Eindhoven Perimeno-
pausal Osteoporosis Study (EPOS) was conducted between
September 1994 and September 1995. All responders gave
their written informed consent and the study was approved
by two medical ethics committees. The study population has
been described in detail before (Smeets-Goevaers et al.,
1998). For the present study, information was available on
6700 Dutch women living in the city of Eindhoven and born
between 1938 and 1948. Two hundred and fifty one women
were non-Caucasian and were excluded from the current ana-
lysis. Women with uncertain menopausal status or age at
menopause were excluded (n ¼ 2942) e.g. women who used
hormone replacement therapy (n ¼ 1608) and those who
reported hysterectomy, oophorectomy or both (n ¼ 775).
Thirty women were excluded because they did not provide
accurate information on reproductive factors and one woman
was excluded because BMD could not be measured.
Women who had not had natural menses for 12 months or
more at the time of measurement were defined postmenopau-
sal. Age at menopause was defined as age at the last men-
strual period. The population for analysis comprised 2420
pre- and 1056 post-menopausal women.
Data collection
BMD of the lumbar spine was measured by dual X-ray absorp-
tiometry (DXA; SA Hologic Europe, Brussels). Height and
weight were measured at the screening of women before
enrolment. Body mass index was calculated as weight in kilo-
grams divided by the square of height in meters. Information
about age at menopause, age at menarche, number of live born
children, number of miscarriages and stillborn children, total
duration of breastfeeding, length of the menstrual cycle, total
duration of oral contraceptive use and smoking habits was
assessed by a questionnaire. Information about the duration
and regularity of the menstrual cycle was available in only a
subset of our data. In the postmenopausal group, the subset
was too small (n ¼ 40) to draw any conclusions, but in the
premenopausal group the number of subjects was reasonably
large (n ¼ 1372). In this subset of the premenopausal group,
we examined the length of the menstrual cycle in relation to
BMD. Smoking habits were recorded in five categories: never,
current $10 cigarettes/day, current ,10 cigarettes/day, past
$10 cigarettes/day and past ,10 cigarettes/day.
Measures of estrogen exposure
An estimation of the total duration of exposure to endoge-
nous estrogens in the postmenopausal group was obtained as
follows: for each woman age at menarche, which indicates
the start of endogenous estrogen production, was subtracted
from age at menopause, which indicates the end of estrogen
production by the ovaries; the total number of reproductive
years. As there is negligible exposure to estrogen in a lactat-
ing woman, the total duration of breastfeeding was sub-
tracted. Similarly, the total duration of oral contraceptive use
was subtracted from the duration of exposure to endogenous
estrogens. The oral contraceptives that were used before
1971–1975 contained a very high dose of synthetic estrogen
and suppressed endogenous estrogen production.
To investigate the added value of each component of the
total duration of endogenous estrogen exposure, we calcu-
lated different measures of exposure varying from the most
elaborate calculation, containing all components, to a ‘calcu-
lation’ consisting only of age at menopause.
In the premenopausal group, it was not possible to design
a cumulative measure for estrogen exposure in the same way
as we did in the postmenopausal group. The use of age at
measurement of BMD instead of menopausal age for the cal-
culation of the number of reproductive years is conceptually
not right, as BMD decreases with chronological age and
increases with age at last menses. Therefore, age at
menarche, adjusted for age, was used as a measure of cumu-
lative exposure to endogenous estrogen in the premenopausal
group. The adjustment for age has to be made because older
people have been exposed to endogenous estrogen for
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a longer period of time, while at the same time age itself has
an independent, negative effect on BMD.
Data analysis
BMD measurements were not sufficiently normally distribu-
ted to be modeled in a linear regression model and were
included after a natural logarithm transformation. Since the
observed changes in BMD with the total duration of exposure
to endogenous estrogens were not large, the resulting coeffi-
cients for the transformed BMD may be interpreted as the
relative change in the untransformed BMD.
The associations between the various estimates of preme-
nopausal endogenous estrogen exposure and BMD in the
postmenopausal group were studied by means of linear
regression analysis in uni- and multivariate models. To deter-
mine whether ‘total duration of exposure to endogenous
estrogens’ is a better predictor for BMD than ‘age at meno-
pause’ we compared the proportion of variance in BMD
explained by the linear regression models. BMD and duration
of estrogen exposure were analyzed as continuous variables.
In the multivariate analyses, adjustments were made for age,
body mass index and smoking. Furthermore, the crude and
adjusted relationships between the separate reproductive fac-
tors and BMD were determined in both the pre- and the post-
menopausal group.
Presence of effect modification of the association between
endogenous estrogen exposure and BMD by other variables
was assessed by adding interaction terms to the linear
regression model. If effect modification was present, the
variables were divided in two categories with the median as
cut-off point. The adjusted estimates are presented for each
category of these variables.
All analyses were performed using the Statistical Analysis
System, version 6.11 (SAS Institute, Cary, NC).
Results
General characteristics of the study population are shown in
Table I. The average BMD in the premenopausal women was
1.045 g/cm2 (SE 0.003) and in the postmenopausal women
0.938 g/cm2 (SE 0.004). The mean age at menopause in the
postmenopausal women was 48.3 (SE 0.13) years and mean
number of reproductive years was 34.9 (SE 0.14). There
were no differences between age at menarche in the preme-
nopausal group and age at menarche in the postmenopausal
group.
Tables II and III show the adjusted estimates of the
relationship between the individual reproductive factors,
body mass index, age and the time since the menopause and
BMD. The adjusted relationship between BMD and age at
menarche, which we used as a cumulative measure for
endogenous estrogen exposure in the premenopausal group,
was not significant. No significant relationships were found
between BMD and the number of live born children, the total
duration of breastfeeding and the total duration of use of oral
contraceptives. The variance in BMD explained by these
reproductive factors was extremely small compared to that of
age at menopause. In the premenopausal group, but not in







Spine BMD, g/cm2 1.013 (0.002) 1.045 (0.003) 0.938 (0.004)
Age, years 50.7 (0.04) 49.9 (0.04) 52.5 (0.07)
Age at menarche, years 13.3 (0.03) 13.3 (0.03) 13.4 (0.05)
Number of live-born children 1.9 (0.02) 1.9 (0.02) 1.9 (0.04)
Number of miscarriages/stillborn children 0.3 (0.01) 0.3 (0.01) 0.4 (0.02)
Total duration of lactation, months 1.7 (0.04) 1.7 (0.05) 1.8 (0.08)
Use of oral contraceptives ever, % 74.6 77.1 68.8
Total duration, for users, of oral contraceptive use, months 77.3 (1.11) 75.6 (1.33) 81.8 (2.05)
Length of the menstrual cycle, daysc – 27.2 (0.00) –
Body mass index, kg/m2 25.3 (0.08) 25.5 (0.09) 25.1 (0.13)
Ever smoked, % 66.6 66.1 67.8
Age at menopause, years – – 48.3 (0.13)
Number of reproductive years – – 34.9 (0.14)
Time since menopause, years – – 4.2 (0.11)
aMean (SE) or %.
bThe number of women given for each group is the maximum number of observations used in the calculations.
cThis variable was studied in 1372 women.
Table II. Adjusted estimatesa for the relationship between bone mineral
density and several reproductive variables in 2420b Dutch
premenopausal women
Variable b (SE) P R2 adj
Body mass index, kg/m2 0.00623 (0.00058) 0.0001* 0.0536
Age, years 20.00570 (0.00124) 0.0001* 0.0536
Age at menarche, years 20.00237 (0.00158) 0.1349 0.0548
Number of live-born children 20.00006 (0.00254) 0.9823 0.0532
Number of miscarriages 0.00760 (0.00357) 0.0334* 0.0550
Total duration of use
of oral contraceptives, years
20.00012 (0.00048) 0.8097 0.0539
Total duration of lactation,
months
0.00107 (0.00104) 0.3044 0.0536
Length of the menstrual
cyclec
20.00132 (0.00098) 0.1779 0.0635
aBody mass index adjusted for age and smoking, age adjusted for body mass
index and smoking. All other variables adjusted for age, body mass index
and smoking.
bThe number of women is the maximum number of observations used in the
calculations.
cThis variable was studied in 1372 women.
*P , 0.05.
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the postmenopausal group, a significant relationship with
BMD was found for the number of miscarriages
(b ¼ 0.00760, SE ¼ 0.00357, P ¼ 0.03), although the pro-
portion of variance in BMD explained by this variable was
only 0.16% (not shown in Table).
Body mass index was significantly associated with BMD
in both the pre- and the post-menopausal group, although its
effect was more pronounced after menopause. In the present
study, body mass index appeared to be the strongest confoun-
der of the relationship between reproductive factors and
BMD.
Chronological age, crude as well as corrected for BMI and
smoking, was not significantly associated with BMD in the
postmenopausal women. In the premenopausal women, an
effect of chronological age was clear but did not explain a
large proportion of variance in BMD (R2 ¼ 0.0047; not
shown in Table). In the postmenopausal group a relatively
strong inverse association with BMD was found for the
time since the menopause. The time since the menopause
explained 4.6% of the variance in BMD (not shown in Table).
We repeated our analyses in the subset of the premenopau-
sal group for which the length of the menstrual cycle was
known. Length of the menstrual cycle was not significantly
associated with BMD and adding this variable to the multi-
variate model did not materially alter the results.
The crude associations between various measures for total
duration of endogenous estrogen exposure and BMD in the
postmenopausal women are shown in Table IV. The models
comprising duration of breastfeeding and/or duration of use
of oral contraceptives did not add to the predictive value of
the number of reproductive years (b ¼ 0.00708, P ¼ 0.0001,
R2 ¼ 0.048). The number of reproductive years was a better
predictor for BMD after the menopause than age at meno-
pause (b ¼ 0.00645, P ¼ 0.0001, R2 ¼ 0.036) or age at
menarche (b ¼ –0.00937, P ¼ 0.0001, R2 ¼ 0.011; unadjus-
ted, not shown in Table) separately.
In both the pre- and the post-menopausal group, none of
the reproductive factors duration of breastfeeding, number of
children, number of miscarriages and total duration of oral
contraceptive use confounded the relationship between age at
menopause, age at menarche or the measures for cumulative
endogenous estrogen exposure and BMD.
The effect of the number of reproductive years appeared to
increase with chronological age (P for interaction 0.02) and
to decrease with time since the menopause (P for interaction
0.02). In Table V, the coefficients for the number of repro-
ductive years in the postmenopausal group, adjusted for age,
body mass index and smoking, are presented in strata of age
and time since the menopause. The relationship between the
number of reproductive years and BMD was stronger in the
women over 52.6 years of age compared to the women
younger than 52.6 years of age. However, this relationship
was weaker in the women whose last menses was more than
2.9 years ago compared to the women whose last menses
was less than 2.9 years ago.
Discussion
In this population of 3476 Dutch women, total endogenous
estrogen exposure predicted BMD levels in pre- and post-
menopausal women. However, the inclusion of more repro-
ductive variables in the calculation of duration of exposure to
endogenous estrogens did not add to the predictive value for
BMD of the number of reproductive years, calculated as age
at menopause minus age at menarche. The relationship
between the number of reproductive years and BMD in post-
menopausal women differed with age and the number of
years since the menopause. No significant associations with
BMD were found for age at menarche, parity, duration of
Table III. Adjusted estimatesa for the relationship between bone mineral
density (g/cm2) and several reproductive variables in 1056b Dutch
postmenopausal women
Variable b (SE) P R2 adj
Body mass index, kg/m2 0.00882 (0.00101) 0.0001* 0.0775
Age, years 20.00057 (0.00190) 0.7669 0.0775
Time since the menopause 20.00893 (0.00123) 0.0001* 0.1213
Age at menarche, years 20.00509 (0.00264) 0.0542 0.0799
Number of live-born children 20.00274 (0.00388) 0.4809 0.0771
Number of miscarriages 0.00230 (0.00555) 0.6793 0.0768
Total duration of use
of oral contraceptives, years
0.00037 (0.00079) 0.6422 0.0768
Total duration of lactation,
months
20.00315 (0.00168) 0.0608 0.0797
aBody mass index adjusted for age and smoking, age adjusted for body mass
index and smoking. All other variables adjusted for age, body mass index
and smoking.
bThe number of women given for each group is the maximum number of
observations used in the calculations.
*P , 0.05.
Table IV. Associations between different measures of total duration of endogenous estrogen exposure and bone mineral
density (g/cm2) in 1056a Dutch postmenopausal women
Measure of total duration of endogenous estrogen exposure Coefficient of linear
regression (SE)b
R2 adj
Age at menopause – age at menarche – total duration of lactation – duration of oc use 0.00276 (0.00060) 0.019
Age at menopause –age at menarche – duration of oc use 0.00275 (0.00060) 0.019
Age at menopause – age at menarche – total duration of lactation 0.00715 (0.00096) 0.049
Age at menopause – age at menarche 0.00708 (0.00096) 0.048
Age at menopause 0.00645 (0.00101) 0.036
a1056 is the maximum number of observations used in the calculations. Occasionally there are missing data, but this
never exceeds 2%.
bP , 0.001 for all estimates.
oc ¼ oral contraceptive.
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breastfeeding, duration of oral contraceptive use and length
of the menstrual cycle.
To appreciate these results, some methodological issues
need to be addressed. The data on reproductive factors were
based on self-report and thus depend on the correctness of
the women’s recollection. Although it has been reported that
women’s recall of their reproductive history is sufficiently
accurate to detect most associations between risk factors and
osteoporosis (Cummings, 1991), the possibility of recall
errors cannot be excluded. However, such recall errors are
likely to be random with respect to BMD and, if present, will
only lead to an underestimation of the effect by biasing esti-
mates towards the null.
As only women who did not use hormone replacement
therapy were included in this study, selection may be present.
The women who did use hormone replacement therapy may
have been the women with a lower than average BMD,
which may have led to a reduced variability in BMD in the
remainder of the population.
The number of reproductive years explained only 4.8% of
the variance in BMD. However, as it has been postulated that
genetic factors may account for up to 80% of the variance in
BMD (Health Council of The Netherlands: Committee on
Osteoporosis, 1998; Rubin et al., 1999), duration of exposure
to endogenous estrogen explains a material proportion of the
remaining 20%. Factors such as physical activity, body mass
index, smoking, and calcium intake may also play a role in
determining BMD (Guthrie et al., 1996; Snelling et al., 2001).
The effect of body mass index on BMD and duration of
exposure to endogenous estrogens in our population is diffi-
cult to interpret. A high body mass index is associated with
more adipose tissue. Adipose tissue is capable of converting
androstendione and testosterone into estrogens and continues
doing so after menopause. At the same time, a high body
mass index means a higher physical load on the bones, which
may increase bone mass (Centraal begeleidingsorgaan voor
de intercollegiale toetsing, 1992). The effect of both pro-
cesses cannot be investigated separately. However, it is likely
that obese people are subject to a lower level of physical
activity (Martinez-Gonzalez et al., 1999), which may
compensate for the increased weight the bones have to carry.
The net effect of these mechanisms is difficult to determine.
To our knowledge, we are the first to examine more
refined models of duration of endogenous estrogen exposure
in relation to BMD. However, a relationship between BMD
and the number of reproductive years has been reported
previously in several studies (Kritz Silverstein and Barrett
Connor 1993; Melton III et al., 1993; Ito et al., 1995; Nguyen
et al., 1995; Grainge et al., 2001). To date, only one study
examined the association between number of reproductive years
and hip fracture mortality. In a prospective study in Norway
with over 60000 women followed up for 29 years, a mortality
rate ratio of 0.5 in women with more than 38 reproductive
years compared to women with fewer than 30 reproductive
years was found (Jacobsen et al., 1998). This finding suggests
that the positive effect of the duration of the reproductive
period on BMD is apparent in the risk of fractures as well.
We found an increase in BMD of 7.4% per 10 years of
endogenous estrogen exposure in women aged ,52.6 years
(P ¼ 0.0001) and 9.3% in women aged $52.6 years
(P ¼ 0.0001). Although other studies reported effects of simi-
lar magnitude, the difference in effect with increasing age has
not been mentioned previously. In our population, higher age
meant a more marked effect of the number of reproductive
years on BMD. However, the strength of the association
decreased with increasing time since the menopause. This is
surprising, for attenuation of the effect both with age and with
the number of years since the menopause, which reflects the
longer time since exposure to high levels of endogenous
estrogens, would be more conceivable. In order to elucidate
these results, we calculated Pearson correlation coefficients for
the two variables. This coefficient was 20.092 (P ¼ 0.0028),
indicating that age and the time since menopause were inver-
sely correlated. In this post-menopausal population, it
appeared, the older women were also the ones whose meno-
pause came at an older age. We have to keep in mind,
however, that although the correlation is significant, the coef-
ficient is also very small. Adjustment for both age and the
time since the menopause in one linear regression model is
not possible, as there is a perfect co-linearity between age,
age at menopause, and time since the menopause.
A lack of a clear effect on BMD for age at menarche is
supported by some authors (Johansson et al., 1993; Parazzini
et al., 1996) but not all (Ito et al., 1995; Tuppurainen et al.,
1995). However, in our population the relationship is signifi-
cant when the groups are combined and the number of
women is larger. It seems to be a small effect that can only
be demonstrated in a large group of people.
In the premenopausal group, but not in the postmenopausal
group, a significant relationship with BMD was found for
the number of miscarriages. A possible explanation for the
positive effect of the number of miscarriages is, that a
miscarriage exposes a woman to the same high levels of
endogenous estrogens as a successful pregnancy but without
an effect of a negative calcium balance. In two previous
studies that investigated the number of abortions, no effect
was found on BMD (Hamed et al., 1992a) or hip fractures
(Parazzini et al., 1996).
In both the pre- and the post-menopausal group,
no significant relationships with BMD were found in
Table V. Adjusted estimates for the relationship between bone mineral
density and number of reproductive years in 1048a Dutch postmenopausal
women, presented by age and time since the menopause
Subgroup n b (SE)b for number of reproductive years P
Age
, 52.6 523 0.00736 (0.00149) 0.0001
. ¼ 52.6 525 0.00934 (0.00171) 0.0001
Time since the menopause
, 2.9 523 0.00682 (0.00351) 0.0524
. ¼ 2.9 525 0.00610 (0.00152) 0.0001
aOf the 1056 women in the postmenopausal group, data on number of repro-
ductive years were missing for two observations and data on covariates for
four observations.
bAll estimates are adjusted for age, body mass index and smoking.
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uni- and multivariate analyses for the total duration of lacta-
tion, the number of live born children and the total duration
of use of oral contraceptives. Although the number of chil-
dren varied between 0 and 9, half of the women in both
groups had just one or two children. The absence of effect
found in our population may therefore be due to lack of vari-
ation in this variable. This might also apply for the duration
of lactation. Furthermore, no data on whether breastfeeding
was complete or incomplete were available.
The absence of effect for total duration of use of oral con-
traceptives cannot be attributed to small variation in this vari-
able, as the range was quite wide. However, the effect of oral
contraceptives on bone mass may be related to the specific
formulation and dose (DeCherney, 1996). The current oral
contraceptives have a much lower dose of estrogen and do
not fully suppress the menstrual cycle. Considering their age,
the women in this study may have been users of first, second
or both generations of oral contraceptives. Thus, it is most
likely that the suppression of endogenous cycles during the
use of oral contraceptives was not complete. Furthermore,
the use of oral contraceptives means the (partial) substitution
of endogenous by exogenous estrogen exposure. Both are
expected to have a positive effect on BMD and therefore it is
possible that although oral contraceptives might suppress the
endogenous cycle, the net effect on BMD is zero.
In this study we investigated only the effect of the duration
of exposure to endogenous estrogens and did not take the
intensity of exposure into account, such as during pregnancy,
when maternal estrogen levels are much higher than during
the normal menstrual cycle. However, the lack of effect found
for pregnancy does not support the existence of an intensity
effect of endogenous estrogens on BMD. During pregnancy
the increased levels of serum estradiol are accompanied by an
increased demand for calcium. It is conceivable that this
results in a net effect of pregnancy that approaches zero.
Studies on the use of exogenous estrogens do indicate an
effect of intensity, as dose-related effects of estrogens on
bone density have been reported (DeCherney, 1996; Speroff
et al., 1996). In general it appears that the effect of hormone
replacement therapy on bone is much larger than that of
endogenous estrogen (Speroff et al., 1996; The writing group
for the PEPI trial, 1996).
In conclusion, this study showed that it is not necessary to
include other reproductive factors than age at menopause and
age at menarche in determining the total duration of
endogenous estrogen exposure in both pre- and post-meno-
pausal women.
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Tuppurainen M, Kröger H, Saarikoski S, Honkanen R and Alhava E (1995)
The effect of gynecological risk factors on lumbar and femoral bone min-
eral density in peri- and postmenopausal women. Maturitas 21,137–145.
Van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC and
Banga JD (1996) Age at menopause as a risk factor for cardiovascular
mortality. Lancet 347,714–718.
Verheul HA, Coelingh-Bennink HJ, Kenemans P, Atsma WJ, Burger CW,
Eden JA, Hammar M, Marsden J and Purdie DW (2000) Effects of estro-
gens and hormone replacement therapy on breast cancer risk and on effi-
cacy of breast cancer therapies. Maturitas 36,1–17.
Vessey M, Mant J and Painter R (1998) Oral contraception and other factors
in relation to hospital referral for fracture. Contraception 57,231–235.
Vico L, Prallet B, Chappard D, Pallot-Prades B, Pupier R and Alexandre C
(1992) Contributions of chronological age, age at menarche and meno-
pause and of anthropometric parameters to axial and peripheral bone den-
sities. Osteoporosis Int 2,153–158.
Zhang Y, Felson DT, Ellison RC, Kreger BE, Schatzkin A, Dorgan JF,
Cupples LA, Levy D and Kiel DP (2001) Bone mass and the risk of colon
cancer among postmenopausal women: the Framingham study. Am J Epi-
demiol 153,31–37.
Zheng T, Holford TR, Mayne ST, Owens PH, Zhang Y, Zhang B, Boyle P
and Zahm SH (2001) Lactation and breast cancer risk: a case-control
study in Connecticut. Br J Cancer 84,1472–1476.
Submitted on October 14, 2003; accepted on May 24, 2004
Endogenous estrogen exposure and BMD
2169
